PMID- 32753884
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 13
DP  - 2020
TI  - Invasive Micropapillary Carcinoma with CEP17 Monosomy of the Bilateral Breast: A 
      Rare Case Report and Review of the Literature.
PG  - 6425-6432
LID - 10.2147/OTT.S251934 [doi]
AB  - Invasive micropapillary carcinoma (IMPC) is a novel type of breast cancer which 
      is potentially very aggressive and may show early lymphatic infiltration. 
      Monosomy of chromosome 17 (m17) is rare in breast cancer, and according to the 
      2018 guidelines of the American Society of Clinical Oncology/College of American 
      Pathologists, the decision to administer trastuzumab treatment should be made 
      based on positive human epidermal growth factor receptor 2 results by 
      immunohistochemistry. Here, we report a rare case of bilateral local advanced 
      IMPC involving m17. A 33-year-old woman found a mass measuring 30 mm on the left 
      breast that increased to 100 mm over 3 months. A diagnosis of IMPC was made based 
      on the findings of core needle biopsies of bilateral breast masses and left 
      axillary lymph node, and m17 was detected by fluorescence in situ hybridization 
      (FISH). The patient underwent 6 cycles of neoadjuvant chemotherapy (docetaxel, 
      epirubicin, and cyclophosphamide) and left-side modified radical mastectomy, left 
      axillary lymph node dissection, right breast-conserving surgery, and right 
      sentinel lymph node biopsy. Postoperative pathologic analysis of both breasts 
      revealed IMPC, and m17 was confirmed by FISH. The patient received radiotherapy 
      and endocrine therapy but rejected trastuzumab treatment. The patient was still 
      alive at the 30-month follow-up, without recurrence or metastasis. Our findings 
      suggest that loss of chromosome 17 may influence prognosis or therapeutic 
      response, which needs to be further confirmed.
CI  - (c) 2020 Zhang et al.
FAU - Zhang, Le
AU  - Zhang L
AUID- ORCID: 0000-0003-4622-5750
AD  - Department of Breast Surgery, The Third Hospital of Jilin University, Changchun, 
      Jilin 130033, People's Republic of China.
FAU - Wang, Yuechen
AU  - Wang Y
AD  - Department of Breast Surgery, Tohoku University Hospital, Sendai, Miyagi 
      980-0000, Japan.
FAU - Zhang, Leichao
AU  - Zhang L
AD  - Department of Pathology, The Third Hospital of Jilin University, Changchun, Jilin 
      130033, People's Republic of China.
FAU - Xing, Hua
AU  - Xing H
AD  - Department of Breast Surgery, The Third Hospital of Jilin University, Changchun, 
      Jilin 130033, People's Republic of China.
FAU - Niu, Chunbo
AU  - Niu C
AD  - Department of Pathology, The Third Hospital of Jilin University, Changchun, Jilin 
      130033, People's Republic of China.
FAU - Yu, Qiong
AU  - Yu Q
AD  - Department of Radiology, The Third Hospital of Jilin University, Changchun, Jilin 
      130033, People's Republic of China.
FAU - Tang, Lu
AU  - Tang L
AUID- ORCID: 0000-0001-9435-152X
AD  - Department of Breast Surgery, The Third Hospital of Jilin University, Changchun, 
      Jilin 130033, People's Republic of China.
LA  - eng
PT  - Case Reports
DEP - 20200702
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC7342458
OTO - NOTNLM
OT  - CEP17
OT  - breast cancer
OT  - chromosome enumeration probe 17
OT  - fluorescence in situ hybridization
OT  - human epidermal growth factor receptor 2
COIS- The authors disclose no potential conflicts of interest.
EDAT- 2020/08/06 06:00
MHDA- 2020/08/06 06:01
PMCR- 2020/07/02
CRDT- 2020/08/06 06:00
PHST- 2020/02/29 00:00 [received]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/08/06 06:01 [medline]
PHST- 2020/07/02 00:00 [pmc-release]
AID - 251934 [pii]
AID - 10.2147/OTT.S251934 [doi]
PST - epublish
SO  - Onco Targets Ther. 2020 Jul 2;13:6425-6432. doi: 10.2147/OTT.S251934. eCollection 
      2020.